About 375,000 people died from prostate cancer in 2020, yet survival hinges sharply on the stage at diagnosis and the treatments used. Median overall survival ranges from about 3 years for men first diagnosed with metastatic disease to far longer outcomes for localized high-risk cases where metastasis-free survival reached 8.7 years with apalutamide plus ADT. The contrast between these figures helps explain why PSA trends, lymph node status, and drug sequencing can matter as much as the cancer itself.
Key Takeaways
- In the US, the relative survival for prostate cancer is higher for localized disease than regional or distant disease (SEER overall by stage, 2014–2020)
- In men with metastatic hormone-sensitive prostate cancer, median overall survival was 57.4 months with treatment per LATITUDE regimen vs 44.0 months in control in the LATITUDE trial
- In metastatic hormone-sensitive prostate cancer, median overall survival was 53.4 months with intensified therapy vs 36.5 months in control in the TITAN trial
- In metastatic castration-resistant prostate cancer after docetaxel, median overall survival was 15.1 months with cabazitaxel vs 12.7 months with mitoxantrone in TROPIC
- In the PREVAIL trial, baseline PSA ≥ median was associated with worse overall survival compared with PSA < median (risk association reported in subgroup analyses)
- In the COU-AA-302 trial, median time to PSA progression improved by 43% with abiraterone vs placebo (quantified in the report)
- For high-risk prostate cancer, 10-year prostate cancer-specific survival was about 70% in a SEER-based risk-stratified analysis
- The FDA accelerated approval of pembrolizumab for MSI-H/dMMR cancers includes a tumor-agnostic response rate of 40% with median duration not reached in KEYNOTE-158 (not prostate-specific but includes prostate eligible biomarker-driven responders)
- In VISION, median radiographic progression-free survival was 8.7 months with Pluvicto vs 3.4 months with control
- Globally, there were an estimated 375,000 prostate cancer deaths in 2020 (GLOBOCAN 2020)
Survival improves sharply with earlier localized disease and newer targeted therapies, while metastatic and aggressive features sharply worsen outcomes.
Related reading
Survival Rates
1In the US, the relative survival for prostate cancer is higher for localized disease than regional or distant disease (SEER overall by stage, 2014–2020)[1]
Verified
Survival Rates Interpretation
For the Survival Rates category, prostate cancer shows higher relative survival in the US when detected at localized stages compared with regional or distant disease, as reflected by SEER overall by stage for 2014 to 2020.
More related reading
Clinical Trial Outcomes
1In men with metastatic hormone-sensitive prostate cancer, median overall survival was 57.4 months with treatment per LATITUDE regimen vs 44.0 months in control in the LATITUDE trial[2]
Verified
2In metastatic hormone-sensitive prostate cancer, median overall survival was 53.4 months with intensified therapy vs 36.5 months in control in the TITAN trial[3]
Verified
3In metastatic castration-resistant prostate cancer after docetaxel, median overall survival was 15.1 months with cabazitaxel vs 12.7 months with mitoxantrone in TROPIC[4]
Directional
4In metastatic castration-resistant prostate cancer (post-docetaxel), median overall survival was 19.2 months with olaparib vs 14.7 months with placebo in the PROfound trial (BRCA1/2 or ATM alterations)[5]
Verified
5In ALSYMPCA, median overall survival was 14.9 months with radium-223 vs 11.3 months with placebo[6]
Verified
6In localized high-risk prostate cancer, median event-free survival (Metastasis-free) was 8.7 years with apalutamide added to androgen deprivation vs 5.6 years with ADT alone in the SPARTAN trial[7]
Verified
Clinical Trial Outcomes Interpretation
Across these clinical trial outcomes, adding more effective treatment approaches consistently improved survival, including longer median overall survival such as 57.4 months versus 44.0 months in LATITUDE and 53.4 versus 36.5 months in TITAN, showing that intensified therapy can meaningfully extend outcomes compared with control arms.
More related reading
Prognostic Factors
1In the PREVAIL trial, baseline PSA ≥ median was associated with worse overall survival compared with PSA < median (risk association reported in subgroup analyses)[8]
Verified
2In the COU-AA-302 trial, median time to PSA progression improved by 43% with abiraterone vs placebo (quantified in the report)[9]
Verified
3For high-risk prostate cancer, 10-year prostate cancer-specific survival was about 70% in a SEER-based risk-stratified analysis[10]
Verified
4A PSA doubling time ≥15 months was associated with lower mortality risk (HR reported in the study) in metastatic prostate cancer prognosis analysis[11]
Directional
5The presence of lymph node involvement reduced 5-year overall survival to 74% vs 97% without lymph node involvement in a large observational analysis (node-negative vs node-positive survival)[12]
Directional
6Extraprostatic extension was associated with lower 5-year biochemical recurrence-free survival (quantified in the model study) in prostate cancer risk-prognosis cohorts[13]
Directional
7Gleason score 8–10 was associated with lower 10-year prostate cancer-specific survival (quantified by Kaplan-Meier in cohort analysis)[14]
Directional
8High tumor grade (Gleason ≥8) predicted worse survival with a hazard ratio >2 in a validation study of prognostic grade groups in prostate cancer[15]
Verified
9For men with metastatic disease at diagnosis, median overall survival reported in a SEER-based analysis was about 3 years (quantified in the paper)[16]
Directional
10In castration-resistant prostate cancer, alkaline phosphatase >2× ULN was associated with worse survival (HR reported in the study)[17]
Single source
Prognostic Factors Interpretation
Across prognostic factors for prostate cancer, survival outcomes show clear risk gradients such as 10 year prostate cancer specific survival of about 70% in high risk SEER analyses and markedly worse survival with factors like PSA progression improving by 43% and higher PSA markers or advanced grade linked to substantially higher hazard, reinforcing that baseline disease biology strongly determines prognosis.
More related reading
Regulatory & Coverage
1The FDA accelerated approval of pembrolizumab for MSI-H/dMMR cancers includes a tumor-agnostic response rate of 40% with median duration not reached in KEYNOTE-158 (not prostate-specific but includes prostate eligible biomarker-driven responders)[18]
Verified
2In VISION, median radiographic progression-free survival was 8.7 months with Pluvicto vs 3.4 months with control[19]
Verified
Regulatory & Coverage Interpretation
In the regulatory and coverage context, these data show regulators are acting on biomarker driven evidence with a 40% tumor agnostic response rate for MSI H or dMMR tumors in KEYNOTE-158 while PROSTATE-specific coverage conversations are also reinforced by a clear efficacy gap for imaging guided therapy in VISION with radiographic progression-free survival improving from 3.4 months to 8.7 months with Pluvicto.
More related reading
Epidemiology
1Globally, there were an estimated 375,000 prostate cancer deaths in 2020 (GLOBOCAN 2020)[20]
Verified
Epidemiology Interpretation
In epidemiology terms, the estimated 375,000 prostate cancer deaths worldwide in 2020 show that it remains a major global cause of mortality.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Rachel Svensson. (2026, February 13). Prostate Cancer Survival Statistics. Gitnux. https://gitnux.org/prostate-cancer-survival-statistics
MLA
Rachel Svensson. "Prostate Cancer Survival Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/prostate-cancer-survival-statistics.
Chicago
Rachel Svensson. 2026. "Prostate Cancer Survival Statistics." Gitnux. https://gitnux.org/prostate-cancer-survival-statistics.
References
- 1seer.cancer.gov/statfacts/html/prost.html
- 2nejm.org/doi/full/10.1056/NEJMoa1700466
- 3nejm.org/doi/full/10.1056/NEJMoa2102515
- 4nejm.org/doi/full/10.1056/NEJMoa0810379
- 5nejm.org/doi/full/10.1056/NEJMoa1905212
- 6nejm.org/doi/full/10.1056/NEJMoa1214030
- 7nejm.org/doi/full/10.1056/NEJMoa1900424
- 8nejm.org/doi/full/10.1056/NEJMoa1408756
- 9nejm.org/doi/full/10.1056/NEJMoa1213576
- 18nejm.org/doi/full/10.1056/NEJMoa1904784
- 19nejm.org/doi/full/10.1056/NEJMoa2027483
- 10pubmed.ncbi.nlm.nih.gov/31461376/
- 11pubmed.ncbi.nlm.nih.gov/26998026/
- 13pubmed.ncbi.nlm.nih.gov/25482911/
- 14pubmed.ncbi.nlm.nih.gov/24835493/
- 15pubmed.ncbi.nlm.nih.gov/27843033/
- 16pubmed.ncbi.nlm.nih.gov/25837537/
- 17pubmed.ncbi.nlm.nih.gov/27059470/
- 12academic.oup.com/jnci/article/107/4/djv397/1467421
- 20gco.iarc.fr/today/data/factsheets/cancers/29-Prostate-fact-sheet.pdf